Xenetic Bio Share Discussion Threads

[heyho2] 20/3/2015 14:48

Finally a bit of life in the patient!

[ashthorpedo] 04/3/2015 11:20

The last 2 quarterly statements have both stated that the company funds would last until middle of the 1st Quarter 2015 as in now.

Cash at 31/3/2014 $10.86m
30/6/2014 $7.61m
30/9/2014 $4.83m

It is plain to see that the company's historical cash burn is more than $1.1m per quarter.

Also from the September Quarterly Statement
"Cash flows used in operating activities for the nine months ended 30 September 2014 totaled approximately $9.5 million,which includes a net loss of approximately $10.0 million, partially offset by $1.7 million in non-cash charges for share-based compensation and loss on disposal of subsidiaries and reduced by approximately $1.4 million in net increase in account receivable
and reductions in accounts payable and accrued expenses. The $9.5 million includes cash expenses of approximately $1.8 million in salaries, wages, employee fringe benefits and related taxes, including scientific staff, $1.9 million in professional consultants, $1.2 million in program-specific clinical development costs, $944,000 in legal fees, $881,000 in accounting and tax consultants,$550,000 in regulatory, investor relations and travel expenses and $154,000 in corporate insurance."

$9.5 million in 9 months equates to over $1m per month.

Perhaps the $1.1m per quarter relates to future cash burn because its easy to see from the above were they could make a few cuts.

[gregoryan] 03/3/2015 20:45

I am confident they will raise the required funds.

[heyho2] 03/3/2015 19:45

Have a read of Ash's post 1212 above!

[gregoryan] 03/3/2015 15:09

heyho2

"No news by the end of Q1 could be curtains..."

Not according to the latest presentation on the Xbio website.

Cash at September 2014 $4.8m.
Cash burn $1.1m/quarter.

By my calculations that gives the company until Q3 to raise funds.

[heyho2] 03/3/2015 13:40

Coming towards the end of Q1 2015 and no sign of additional financing being announced. I'm beginning to think this move to the U.S. was a major duck-up!No news by the end of Q1 could be curtains...

[corrientes] 25/2/2015 17:18

What a damp squib ! Looks like another one for the bin.

[ashthorpedo] 11/2/2015 12:09

Look like we are going down to the wire here. Piggy bank just about empty.

From the last quarterly statement

"if the Company does not raise additional working capital by the end of 2014, there is no assurance that the Company would be able to continue its operations as now currently planned beyond the middle of the first quarter of 2015 and could raise substantial doubt over the Company’s ability to continue as a going concern."

We should be due another quarterly statement next week so hopefully we will get some good news Re: funding.

[trotterstrading] 23/1/2015 12:51

My take on the conference call:

1) Cash Injection into the company expected in the next few months

2) Board and Managers of Xenetic to participate in any funding arrangement

4) Nasdaq uplift by FEB 16 (AT THE LATEST)

5) EPO out-license possibly this year

6) Significant interest in Xenetic from 39 out of 40 Institutional Investors

7) Oncohist could be MASSIVE for this share - AML + Another soon-to-be announced filing are just the begining for this mollecule (Dana Farber found Oncohist had an impact on 60 cancer cell lines in vitro!!)


On a more general note, I guess it's easy for us long term shareholders to be sanguine about Xenetic as we have had a long painful road, and the future is still not a guaranteed success story, but never the less I can’t help but get excited about our product pipeline and sheer potential of this share, my firm view if that Xenetic will go stratospheric if/when we get Nasdaq uplift, when that announcement finally comes I will be increasing my position in readiness for the big day!

All the best

[heyho2] 20/1/2015 22:41

Thanks Ash

[ashthorpedo] 20/1/2015 22:13

Go to the company website events and presentations

[heyho2] 20/1/2015 18:48

TrottersCouldn't make it but would really appreciate the key points if you're able to post it!Thanks

[trotterstrading] 20/1/2015 15:23

Anyone else attend today's conference call with Scott and Colin?

I came away fairly confident, hopefully the light at the end of the tunnel is months away rather than years!

[heyho2] 10/1/2015 18:21

Oh and...Looking aheadWe are excited about the many milestones we look to achieve during 2015. Among these are further results from the Phase 2 ErepoXen clinical trial being conducted in Australia and New Zealand. In addition, we plan to complete enabling studies for OncoHist in order to file an Investigational New Drug application with the FDA in AML, to initiate a Phase 2a study in 2015 in AML and possibly to initiate an additional Phase 2a study in another leukemia indication. We also plan to submit an orphan drug application in the U.S. and the EU for OncoHist in an additional hematology indication.One of our goals in 2014 was to list our common stock on the NASDAQ market. While we were not able to do so this past year, we remain committed to that goal as a priority for the Company; however, we cannot predict at this time when this may occur.Lastly, we invite you to view our updated corporate Fact Sheet, which contains further information on our milestones and growth strategy. You may access it by clicking here. We look forward to keeping you abreast of our progress and plans via periodic public conference calls, and plan to hold the next one in the first months of 2015. We will announce details of the call approximately one week prior.I would like to thank our employees, business partners and shareholders for their support throughout the year. We have great technologies, great IP, great programs, great partners and a robust management team that will leave no stone unturned to leverage our assets to deliver shareholder value.

[heyho2] 10/1/2015 18:21

Just noticed this from December, key points are:LEXINGTON, Mass.--(BUSINESS WIRE)--Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that CEO M. Scott Maguire has written a Letter to Shareholders, the full text of which appears below:To Our Shareholders:The year 2014 at Xenetic Biosciences has been defined by a number of significant achievements. As I review all the activities of the past year I am, quite frankly, extremely excited and proud to share with you our considerable accomplishments and to review our plans to build upon that momentum in 2015. Key highlights of 2014 included:We completed a complex merger transaction between the former UK public company Xenetic Biosciences plc and the U.S. public company General Sales and Leasing Inc. in January, and the company's common stock began trading in the U.S. on the OTCBB under the symbol XBIO.Within days of our listing in the U.S., Baxter International made a $10 million equity investment in our company at a price of $0.935 per share.Accompanying this Baxter investment was an amendment to our license agreement with them for their next-generation PSA-rFactorVIII product. Our agreement with Baxter now calls for potential cash milestones of up to $100 million, plus substantial sales royalties should the product meet its clinical objectives and, ultimately, be approved for market launch.We opened our new corporate headquarters and research and development facility in Lexington, Massachusetts. Like other UK- and European-based companies, Xenetic has come to greater Boston to be at the heart of the U.S. biotech industry. We hired several senior industry personnel including MIT-educated Dr. Curt Lockshin as VP of Research and Operations to work alongside Dr. Henry Hoppe, VP of Drug Development and a former senior member of Genzyme. We now believe we have a team with talent that would rival any of our larger peers.We added healthcare industry veterans to our Board of Directors, including Mark Leuchtenberger as Non-Executive Chairman and Timothy Cote, M.D., MPH, the Former Head of the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development.We made excellent clinical progress with our ErepoXen®, PSA-OExyntomodulin, PulmoXen™ and OncoHist™ programs, reporting the successful clinical data over the course of the year.We now have six drug candidates that have reported positive clinical news across eight therapeutic areas.A world-leading key opinion leader in blood cancers, presented data on OncoHist at the American Society of Hematology (ASH) Annual Meeting last week.

[digger18] 08/1/2015 13:12

It would seem that 3,244,784 shares were issued for intellectual property, so yes a dilution. However, the rest currently unexercised warrants based on a Min share price of $0.77 and also performance criteria. So IMHO would not have thought this would be the main cause of the share price fall. I see the main issue being an expected placing in order to raise capital required by end of Feb 2015. Ie uncertainty of the likelihood,source and extent of the capital raising.

[heyho2] 07/1/2015 22:07

Now I know why the price has been falling, it's a placing by any other name:On December 31, 2014, Xenetic Biosciences, Inc. (the "Company") entered into an Intellectual Property Assignment (the "IP Assignment") with Dmitry Genkin, FDS Pharma and Lipoxen Technologies Limited, providing for the assignment of certain intellectual property rights by Dmitry Genkin and FDS Pharma to Lipoxen Technologies Limited, a wholly-owned subsidiary of the Company, and in consideration thereof, the Company's issuance of 3,244,784 shares of its common stock, par value $0.01 per share ("Common Stock"), to FDS Pharma. Mr. Genkin is affiliated with FDS Pharma and our collaborators, Synbio and Pharmsynthez. Please refer to Part I - Item 1 of the Company's Annual Report on Form 10-K filed on April 15, 2014 (the "Form 10-K"), under the caption "Significant Co-Development Collaborations and Strategic Arrangements" and elsewhere in the Form 10-K for a further discussion of the Company's affiliations and collaborations. On December 31, 2014, the Company issued (i) a warrant (the "Synbio Warrant") to purchase 6,745,000 shares of Common Stock to Synbio LLC, a principal shareholder and collaborator of the Company ("Synbio"), (ii) a warrant to purchase 1,600,000 shares of Common Stock to Firdaus Jal Dastoor, a director of the Company and (iii) a warrant (the "Serum Warrant") to purchase 3,200,000 shares of Common Stock to Serum Institute of India Limited, a principal shareholder and collaborator of the Company ("Serum") (collectively, the "Warrants"). The initial exercise price of these Warrants is the higher of $0.77 per share or the Fair Market Value (as defined in the Warrants). These Warrants have a five-year term. The Synbio Warrant and Serum Warrant are subject to vesting. This vesting is contingent on the achievement, on the part of Synbio and Serum, of certain clinical and regulatory milestones (in the Russian Federation and the Commonwealth of Independent States with respect to the Synbio Warrant and in India or certain other territories outside the United States with respect to the Serum Warrant) within prescribed timelines in connection with certain drug candidates that are included within the Company's collaborative arrangements with those entities. In addition, the Synbio Warrant replaced the warrant dated August 4, 2011 issued by Lipoxen Plc to Synbio LLC. The warrant to Firdaus Jal Dastoor was issued in consideration of Dastoor's long-term valuable support to the Company. Please refer to the Company's Form 10-K, under the caption "Significant Co-Development Collaborations and Strategic Arrangements" and elsewhere in the Form 10-K for a further discussion of the Company's collaborative arrangements with those entities. On December 31, 2014, subject to compliance with the applicable securities laws, the board of directors of the Company has approved the issuance of warrants to purchase an aggregate of 480,000 shares of Common Stock to certain non-director designees of Synbio, Serum and Pharmsynthez. The warrants to be issued to Synbio designees and Pharmsynthez designees are expected to be in substantially the same form as the Synbio warrant. The warrants to be issued to Serum designees are expected to be in substantially the same form as the Serum warrant. Accordingly, these warrants are expected to carry similar contingent vesting requirements.

[buywell2] 24/12/2014 10:19

At current SP

Funds in the USA would I think be interested in taking a stake

Will a Western EPO Partner come in before this happens ?

[holly_dog] 19/12/2014 12:35

Looks like a Western trial result showing this works. Very exciting, finally!

[ashthorpedo] 19/12/2014 12:04

Scott has been banging on about how excited he is about Oncohist for the past 2 years and we were promised data from the trials in Russia for the past year. If the results from these trials that Scott is privy to are so exciting the falling share price would be solved in an instant and liquidity would increase.

Why has the release of the results of these trials been delayed?